Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Wood, TF; DiFronzo, LA; Rose, DM; Haigh, PL; Stern, SL; Wanek, L; Essner, R; Morton, DL
   Does complete, resection of melanoma metastatic to solid intra-abdominal organs improve survival?
   ANNALS OF SURGICAL ONCOLOGY
   
   T.F. Wood et al., "Does complete, resection of melanoma metastatic to solid intra-abdominal organs improve survival?", ANN SURG O, 8(8), 2001, pp. 658-662
2. Habal, N; Gupta, RK; Bilchik, AJ; Yee, R; Leopoldo, Z; Ye, W; Elashoff, RM; Morton, DL
   CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer
   ANNALS OF SURGICAL ONCOLOGY
   
   N. Habal et al., "CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer", ANN SURG O, 8(5), 2001, pp. 389-401
3. Tsioulias, GJ; Gupta, RK; Tisman, G; Hsueh, EC; Essner, R; Wanek, LA; Morton, DL
   Serum TA90 antigen-antibody complex as a surrogate marker for the efficacyof a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma
   ANNALS OF SURGICAL ONCOLOGY
   
   G.J. Tsioulias et al., "Serum TA90 antigen-antibody complex as a surrogate marker for the efficacyof a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma", ANN SURG O, 8(3), 2001, pp. 198-203
4. Wood, TF; Saha, S; Morton, DL; Tsioulias, GJ; Rangel, D; Hutchinson, W; Foshag, LJ; Bilchik, AJ
   Validation of lymphatic mapping in colorectal cancer: In vivo, ex vivo, and laparoscopic techniques
   ANNALS OF SURGICAL ONCOLOGY
   
   T.F. Wood et al., "Validation of lymphatic mapping in colorectal cancer: In vivo, ex vivo, and laparoscopic techniques", ANN SURG O, 8(2), 2001, pp. 150-157
5. Wood, TF; Spirt, M; Rangel, D; Shen, P; Tsioulias, GJ; Morton, DL; Bilchik, AJ
   Lymphatic mapping improves staging during laparoscopic colectomy for cancer
   SURGICAL ENDOSCOPY-ULTRASOUND AND INTERVENTIONAL TECHNIQUES
   
   T.F. Wood et al., "Lymphatic mapping improves staging during laparoscopic colectomy for cancer", SURG ENDOSC, 15(7), 2001, pp. 715-719
6. Cochran, AJ; Morton, DL; Stern, S; Lana, AMA; Essner, R; Wen, DR
   Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment
   MODERN PATHOLOGY
   
   A.J. Cochran et al., "Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment", MOD PATHOL, 14(6), 2001, pp. 604-608
7. Bilchik, AJ; Saha, S; Wiese, D; Stonecypher, JA; Wood, TF; Sostrin, S; Turner, RR; Wang, HJ; Morton, DL; Hoon, DSB
   Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase II trial
   JOURNAL OF CLINICAL ONCOLOGY
   
   A.J. Bilchik et al., "Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase II trial", J CL ONCOL, 19(4), 2001, pp. 1128-1136
8. Kelley, MC; Gupta, RK; Hsueh, EC; Yee, R; Stern, S; Morton, DL
   Tumor-associated antigen TA90 immune complex assay predicts recurrence andsurvival after surgical treatment of stage I-III melanoma
   JOURNAL OF CLINICAL ONCOLOGY
   
   M.C. Kelley et al., "Tumor-associated antigen TA90 immune complex assay predicts recurrence andsurvival after surgical treatment of stage I-III melanoma", J CL ONCOL, 19(4), 2001, pp. 1176-1182
9. Balch, CM; Buzaid, AC; Soong, SJ; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Gershenwald, JE; Houghton, A; Kirkwood, JM; McMasters, KM; Mihm, MF; Morton, DL; Reintgen, DS; Ross, MI; Sober, A; Thompson, JA; Thompson, JF
   Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma
   JOURNAL OF CLINICAL ONCOLOGY
   
   C.M. Balch et al., "Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma", J CL ONCOL, 19(16), 2001, pp. 3635-3648
10. Morton, DL
    Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma
    TUMORI
    
    D.L. Morton, "Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma", TUMORI, 87(4), 2001, pp. S57-S59
11. Habal, N; Giuliano, AE; Morton, DL
    The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer
    SEMINARS IN ONCOLOGY
    
    N. Habal et al., "The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer", SEMIN ONCOL, 28(1), 2001, pp. 41-52
12. Taback, B; Fujiwara, Y; Wang, HJ; Foshag, LJ; Morton, DL; Hoon, DSB
    Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients
    CANCER RESEARCH
    
    B. Taback et al., "Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients", CANCER RES, 61(15), 2001, pp. 5723-5726
13. Haigh, PI; Lucci, A; Turner, RR; Bostick, PJ; Krasne, DL; Stern, SL; Morton, DL
    Carbon dye histologically confirms the identity of sentinel lymph nodes incutaneous melanoma
    CANCER
    
    P.I. Haigh et al., "Carbon dye histologically confirms the identity of sentinel lymph nodes incutaneous melanoma", CANCER, 92(3), 2001, pp. 535-541
14. DiFronzo, LA; Wanek, LA; Morton, DL
    Earlier diagnosis sf second primary melanoma confirms the benefits of patient education and routine postoperative follow-up
    CANCER
    
    L.A. DiFronzo et al., "Earlier diagnosis sf second primary melanoma confirms the benefits of patient education and routine postoperative follow-up", CANCER, 91(8), 2001, pp. 1520-1524
15. Ravindranath, MH; Gonzales, A; Soh, D; Nishimoto, K; Tam, WY; Bilchik, A; Morton, DL; O'Day, S
    Interleukin-2 binds to ganglioside GD(1b)
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    M.H. Ravindranath et al., "Interleukin-2 binds to ganglioside GD(1b)", BIOC BIOP R, 283(2), 2001, pp. 369-373
16. Rose, DM; Essner, R; Hughes, TMD; Tang, PCY; Bilchik, A; Wanek, LA; Thompson, JF; Morton, DL
    Surgical resection for metastatic melanoma to the liver - The John Wayne Cancer Institute and Sydney Melanoma Unit Experience
    ARCHIVES OF SURGERY
    
    D.M. Rose et al., "Surgical resection for metastatic melanoma to the liver - The John Wayne Cancer Institute and Sydney Melanoma Unit Experience", ARCH SURG, 136(8), 2001, pp. 950-955
17. Broelsch, C; Brennan, MF; Niederhuber, JE; Wanebo, HJ; Morton, DL
    Results of hepatic resection for sarcoma metastatic to liver - Discussion
    ANNALS OF SURGERY
    
    C. Broelsch et al., "Results of hepatic resection for sarcoma metastatic to liver - Discussion", ANN SURG, 234(4), 2001, pp. 547-548
18. Nakayama, T; Taback, B; Turner, R; Morton, DL; Hoon, DSB
    Molecular clonality of in-transit melanoma metastasis
    AMERICAN JOURNAL OF PATHOLOGY
    
    T. Nakayama et al., "Molecular clonality of in-transit melanoma metastasis", AM J PATH, 158(4), 2001, pp. 1371-1378
19. Shen, P; Conforti, AM; Essner, R; Cochran, AJ; Turner, RR; Morton, DL
    Is the node of Cloquet the sentinel node for the iliac/obturator node group?
    CANCER JOURNAL
    
    P. Shen et al., "Is the node of Cloquet the sentinel node for the iliac/obturator node group?", CANCER J, 6(2), 2000, pp. 93-97
20. Balch, CM; Morton, DL
    Second-time surgery for stage IV sarcoma (A model of sequential metastases)
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    
    C.M. Balch e D.L. Morton, "Second-time surgery for stage IV sarcoma (A model of sequential metastases)", J AM COLL S, 191(2), 2000, pp. 193-195
21. Chan, AD; Essner, R; Wanek, LA; Morton, DL
    Judging the therapeutic value of lymph node dissections for melanaoma
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    
    A.D. Chan et al., "Judging the therapeutic value of lymph node dissections for melanaoma", J AM COLL S, 191(1), 2000, pp. 16-22
22. Chan, AD; Essner, R; Wanek, LA; Morton, DL
    Judging the therapeutic value of lymph node dissections for melanaoma - Reply
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    
    A.D. Chan et al., "Judging the therapeutic value of lymph node dissections for melanaoma - Reply", J AM COLL S, 191(1), 2000, pp. 23-23
23. Shen, P; Wanek, LA; Morton, DL
    Is adjuvant radiotherapy necessary after positive lymph node dissection inhead and neck melanomas?
    ANNALS OF SURGICAL ONCOLOGY
    
    P. Shen et al., "Is adjuvant radiotherapy necessary after positive lymph node dissection inhead and neck melanomas?", ANN SURG O, 7(8), 2000, pp. 554-559
24. Habal, N; Gupta, RK; Bilchik, AJ; Johnson, T; Morton, DL
    TA90-IC, a new marker for advanced colon cancer
    ANNALS OF SURGICAL ONCOLOGY
    
    N. Habal et al., "TA90-IC, a new marker for advanced colon cancer", ANN SURG O, 7(5), 2000, pp. 352-356
25. Hsueh, EC; Gupta, RK; Yee, R; Leopoldo, ZC; Qi, K; Morton, DL
    Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?
    ANNALS OF SURGICAL ONCOLOGY
    
    E.C. Hsueh et al., "Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?", ANN SURG O, 7(3), 2000, pp. 232-238
26. Shen, P; Guenther, JM; Wanek, LA; Morton, DL
    Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?
    ANNALS OF SURGICAL ONCOLOGY
    
    P. Shen et al., "Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?", ANN SURG O, 7(2), 2000, pp. 114-119
27. Ravindranath, MH; Shen, P; Habal, N; Soh, D; Nishimoto, K; Gonzales, A; Tam, WY; Bilchik, A; Morton, DL
    Does human melanoma express carcinoembryonic antigen?
    ANTICANCER RESEARCH
    
    M.H. Ravindranath et al., "Does human melanoma express carcinoembryonic antigen?", ANTICANC R, 20(5A), 2000, pp. 3083-3092
28. Cochran, AJ; Elashoff, D; Morton, DL; Elashoff, R
    Individualized prognosis for melanoma patients
    HUMAN PATHOLOGY
    
    A.J. Cochran et al., "Individualized prognosis for melanoma patients", HUMAN PATH, 31(3), 2000, pp. 327-331
29. Essner, R; Bostick, PJ; Glass, EC; Foshag, LJ; Haigh, PI; Wang, HJ; Morton, DL
    Standardized probe-directed sentinel node dissection in melanoma
    SURGERY
    
    R. Essner et al., "Standardized probe-directed sentinel node dissection in melanoma", SURGERY, 127(1), 2000, pp. 26-31
30. Essner, R; Huynh, Y; Nguyen, T; Morton, DL; Hoon, DSB
    Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: Novel targets for immune therapy
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
    
    R. Essner et al., "Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: Novel targets for immune therapy", J THOR SURG, 119(1), 2000, pp. 10-20
31. Hoon, DSB; Bostick, P; Kuo, C; Okamoto, T; Wang, HJ; Elashoff, R; Morton, DL
    Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence
    CANCER RESEARCH
    
    D.S.B. Hoon et al., "Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence", CANCER RES, 60(8), 2000, pp. 2253-2257
32. Cochran, AJ; Balda, BR; Starz, H; Bachter, D; Krag, DN; Cruse, CW; Pijpers, R; Morton, DL
    The Augsburg consensus - Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies
    CANCER
    
    A.J. Cochran et al., "The Augsburg consensus - Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies", CANCER, 89(2), 2000, pp. 236-241
33. Chu, KU; Ravindranath, NH; Gonzales, A; Nishimoto, K; Tam, WY; Soh, D; Bilchik, A; Katopodis, N; Morton, DL
    Gangliosides as targets for immunotherapy for pancreatic Adenocarcinoma
    CANCER
    
    K.U. Chu et al., "Gangliosides as targets for immunotherapy for pancreatic Adenocarcinoma", CANCER, 88(8), 2000, pp. 1828-1836
34. Balch, CM; Buzaid, AC; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Houghton, A; Kirkwood, JM; Mihm, MF; Morton, DL; Reintgen, D; Ross, MI; Sober, A; Soong, SJ; Thompson, JA; Thompson, JF; Gershenwald, JE; McMasters, KM
    A new American Joint Committee on Cancer staging system for cutaneous melanoma
    CANCER
    
    C.M. Balch et al., "A new American Joint Committee on Cancer staging system for cutaneous melanoma", CANCER, 88(6), 2000, pp. 1484-1491
35. Tsioulias, GJ; Wood, TF; Morton, DL; Bilchik, AJ
    Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms
    ARCHIVES OF SURGERY
    
    G.J. Tsioulias et al., "Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms", ARCH SURG, 135(8), 2000, pp. 926-931
36. Bilchik, AJ; Wood, TF; Allegra, D; Tsioulias, GJ; Chung, M; Rose, DM; Ramming, KP; Morton, DL
    Cryosurgical ablation and radiofrequency ablation for unresectable hepaticmalignant neoplasms - A proposed algorithm
    ARCHIVES OF SURGERY
    
    A.J. Bilchik et al., "Cryosurgical ablation and radiofrequency ablation for unresectable hepaticmalignant neoplasms - A proposed algorithm", ARCH SURG, 135(6), 2000, pp. 657-662
37. Wood, TF; Tsioulias, GJ; Morton, DL; Rangel, D; Hutchinson, W; Foshag, LJ; Turner, RR; Bilchik, AJ
    Focused examination of sentinel lymph nodes upstages early colorectal carcinoma
    AMERICAN SURGEON
    
    T.F. Wood et al., "Focused examination of sentinel lymph nodes upstages early colorectal carcinoma", AM SURG, 66(11), 2000, pp. 998-1003
38. Morton, DL; Chan, AD
    The concept of sentinel node localization: How it started
    SEMINARS IN NUCLEAR MEDICINE
    
    D.L. Morton e A.D. Chan, "The concept of sentinel node localization: How it started", SEM NUC MED, 30(1), 2000, pp. 4-10
39. Essner, R; Stern, S; Bostick, P; Morton, DL
    Results of lymphatic mapping in melanoma
    LYMPHATIC MAPPING AND PROBE APPLICATIONS IN ONCOLOGY
    
    R. Essner et al., "Results of lymphatic mapping in melanoma", LYMPHATIC MAPPING AND PROBE APPLICATIONS IN ONCOLOGY, 2000, pp. 101-123
40. Cochran, AJ; Wen, DR; Morton, DL
    Surgical pathology of dye-directed selective lymph node dissection
    LYMPHATIC MAPPING AND PROBE APPLICATIONS IN ONCOLOGY
    
    A.J. Cochran et al., "Surgical pathology of dye-directed selective lymph node dissection", LYMPHATIC MAPPING AND PROBE APPLICATIONS IN ONCOLOGY, 2000, pp. 125-139
41. Bilchik, AJ; Rose, DM; Allegra, DP; Bostick, PJ; Hsueh, E; Morton, DL
    Radiofrequency ablation: A minimally invasive technique with multiple applications
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    
    A.J. Bilchik et al., "Radiofrequency ablation: A minimally invasive technique with multiple applications", CA J SCI AM, 5(6), 1999, pp. 356-361
42. Kelemen, PR; Essner, R; Foshag, LJ; Morton, DL
    Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    
    P.R. Kelemen et al., "Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma", J AM COLL S, 189(3), 1999, pp. 247-252
43. Morton, DL; Chan, AD
    Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care?
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    
    D.L. Morton e A.D. Chan, "Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care?", J AM COLL S, 189(2), 1999, pp. 214-223
44. Haigh, PI; Essner, R; Wardlaw, JC; Stern, SL; Morton, DL
    Long-term survival after complete resection of melanoma metastatic to the adrenal gland
    ANNALS OF SURGICAL ONCOLOGY
    
    P.I. Haigh et al., "Long-term survival after complete resection of melanoma metastatic to the adrenal gland", ANN SURG O, 6(7), 1999, pp. 633-639
45. DiFronzo, LA; Wanek, LA; Elashoff, R; Morton, DL
    Increased incidence of second primary melanoma in patients with a previouscutaneous melanoma
    ANNALS OF SURGICAL ONCOLOGY
    
    L.A. DiFronzo et al., "Increased incidence of second primary melanoma in patients with a previouscutaneous melanoma", ANN SURG O, 6(7), 1999, pp. 705-711
46. Essner, R; Conforti, A; Kelley, MC; Wanek, L; Stern, S; Glass, E; Morton, DL
    Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma
    ANNALS OF SURGICAL ONCOLOGY
    
    R. Essner et al., "Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma", ANN SURG O, 6(5), 1999, pp. 442-449
47. Morton, DL; Bostick, PJ
    Will the true sentinel node please stand? Reply
    ANNALS OF SURGICAL ONCOLOGY
    
    D.L. Morton e P.J. Bostick, "Will the true sentinel node please stand? Reply", ANN SURG O, 6(5), 1999, pp. 515-516
48. Kelemen, PR; Wanek, LA; Morton, DL
    Lymph node biopsy does not impair survival after therapeutic dissection for palpable melanoma metastases
    ANNALS OF SURGICAL ONCOLOGY
    
    P.R. Kelemen et al., "Lymph node biopsy does not impair survival after therapeutic dissection for palpable melanoma metastases", ANN SURG O, 6(2), 1999, pp. 139-143
49. Ollila, DW; Foshag, LJ; Essner, R; Stern, SL; Morton, DL
    Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma
    ANNALS OF SURGICAL ONCOLOGY
    
    D.W. Ollila et al., "Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma", ANN SURG O, 6(2), 1999, pp. 150-154
50. Morton, DL; Bostick, PJ
    Will the true sentinel node please stand?
    ANNALS OF SURGICAL ONCOLOGY
    
    D.L. Morton e P.J. Bostick, "Will the true sentinel node please stand?", ANN SURG O, 6(1), 1999, pp. 12-14
51. O'Day, SJ; Gammon, G; Boasberg, PD; Martin, MA; Kristedja, TS; Guo, M; Stern, S; Edwards, S; Fournier, P; Weisberg, M; Cannon, M; Fawzy, NW; Johnson, TD; Essner, R; Foshag, LJ; Morton, DL
    Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    S.J. O'Day et al., "Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma", J CL ONCOL, 17(9), 1999, pp. 2752-2761
52. Bostick, PJ; Morton, DL; Turner, RR; Huynh, KT; Wang, HJ; Elashoff, R; Essner, R; Hoon, DSB
    Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients
    JOURNAL OF CLINICAL ONCOLOGY
    
    P.J. Bostick et al., "Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients", J CL ONCOL, 17(10), 1999, pp. 3238-3244
53. Lavine, SD; Petrovich, Z; Cohen-Gadol, AA; Masri, LS; Morton, DL; O'Day, SJ; Essner, R; Zelman, V; Yu, C; Luxton, G; Apuzzo, MLJ
    Gamma knife radiosurgery for metastatic melanoma: An analysis of survival,outcome, and complications
    NEUROSURGERY
    
    S.D. Lavine et al., "Gamma knife radiosurgery for metastatic melanoma: An analysis of survival,outcome, and complications", NEUROSURGER, 44(1), 1999, pp. 59-64
54. Morton, DL; Ollila, DW
    Critical review of the sentinel node hypothesis
    SURGERY
    
    D.L. Morton e D.W. Ollila, "Critical review of the sentinel node hypothesis", SURGERY, 126(5), 1999, pp. 815-819
55. Lucci, A; Turner, RR; Morton, DL
    Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection
    SURGERY
    
    A. Lucci et al., "Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection", SURGERY, 126(1), 1999, pp. 48-53
56. Ollila, DW; Hsueh, EC; Stern, SL; Morton, DL
    Metastasectomy for recurrent stage IV melanoma
    JOURNAL OF SURGICAL ONCOLOGY
    
    D.W. Ollila et al., "Metastasectomy for recurrent stage IV melanoma", J SURG ONC, 71(4), 1999, pp. 209-213
57. Ollila, DW; Morton, DL
    Tumor doubling time and survival
    JOURNAL OF SURGICAL ONCOLOGY
    
    D.W. Ollila e D.L. Morton, "Tumor doubling time and survival", J SURG ONC, 71(4), 1999, pp. 249-249
58. Takahashi, T; Johnson, TD; Nishinaka, Y; Morton, DL; Irie, RF
    IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlatewith survival of melanoma patients
    JOURNAL OF INVESTIGATIVE DERMATOLOGY
    
    T. Takahashi et al., "IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlatewith survival of melanoma patients", J INVES DER, 112(2), 1999, pp. 205-209
59. Fujiwara, Y; Chi, DDJ; Wang, HJ; Keleman, P; Morton, DL; Turner, R; Hoon, DSB
    Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients
    CANCER RESEARCH
    
    Y. Fujiwara et al., "Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients", CANCER RES, 59(7), 1999, pp. 1567-1571
60. Hsueh, EC; Lucci, A; Qi, K; Morton, DL
    Survival of patients with melanoma of the lower extremity decreases with distance from the trunk
    CANCER
    
    E.C. Hsueh et al., "Survival of patients with melanoma of the lower extremity decreases with distance from the trunk", CANCER, 85(2), 1999, pp. 383-388
61. Hsueh, EC; Nathanson, L; Foshag, LJ; Essner, R; Nizze, JA; Stern, SL; Morton, DL
    Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
    CANCER
    
    E.C. Hsueh et al., "Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases", CANCER, 85(10), 1999, pp. 2160-2169
62. Morton, DL; Ollila, DW; Hsueh, EC; Essner, R; Gupta, RK
    Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma
    CA-A CANCER JOURNAL FOR CLINICIANS
    
    D.L. Morton et al., "Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma", CA-A CANC J, 49(2), 1999, pp. 101
63. Morton, DL; Thompson, JF; Essner, R; Elashoff, R; Stern, SL; Nieweg, OE; Roses, DF; Karakousis, CP; Mozzillo, N; Reintgen, D; Wang, HJ; Glass, EC; Cochran, AJ
    Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial
    ANNALS OF SURGERY
    
    D.L. Morton et al., "Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial", ANN SURG, 230(4), 1999, pp. 453-463
64. Balch, CM; Morton, DL; Bland, KI; Wanebo, HJ
    Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial - Discussion
    ANNALS OF SURGERY
    
    C.M. Balch et al., "Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial - Discussion", ANN SURG, 230(4), 1999, pp. 463-465
65. KELLEY MC; OLLILA DW; MORTON DL
    LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY FOR MELANOMA
    Seminars in surgical oncology
    
    M.C. Kelley et al., "LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY FOR MELANOMA", Seminars in surgical oncology, 14(4), 1998, pp. 283-290
66. OLLILA DW; KELLEY MC; GAMMON G; MORTON DL
    OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS
    Seminars in surgical oncology
    
    D.W. Ollila et al., "OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS", Seminars in surgical oncology, 14(4), 1998, pp. 328-336
67. Bilchik, AJ; Giuliano, A; Essner, R; Bostick, P; Kelemen, P; Foshag, LJ; Sostrin, S; Turner, RR; Morton, DL
    Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    
    A.J. Bilchik et al., "Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms", CA J SCI AM, 4(6), 1998, pp. 351-358
68. KUO CT; BOSTICK PJ; IRIE RF; MORTON DL; CONRAD AJ; HOON DSB
    ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL
    Clinical cancer research
    
    C.T. Kuo et al., "ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL", Clinical cancer research, 4(2), 1998, pp. 411-418
69. KUO CT; BOSTICK PJ; IRIE RF; MORTON DL; CONRAD AJ; HOON DSB
    ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL
    Clinical cancer research
    
    C.T. Kuo et al., "ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL", Clinical cancer research, 4(2), 1998, pp. 411-418
70. MORTON DL
    MINIMALLY INVASIVE STAGING OF PATIENTS WITH MELANOMA - SENTINEL LYMPHADENECTOMY AND DETECTION OF THE MELANOMA-SPECIFIC PROTEINS MART-1 AND TYROSINASE BY REVERSE-TRANSCRIPTASE POLYMERASE-CHAIN-REACTION - INVITED COMMENTARY
    Journal of the American College of Surgeons
    
    D.L. Morton, "MINIMALLY INVASIVE STAGING OF PATIENTS WITH MELANOMA - SENTINEL LYMPHADENECTOMY AND DETECTION OF THE MELANOMA-SPECIFIC PROTEINS MART-1 AND TYROSINASE BY REVERSE-TRANSCRIPTASE POLYMERASE-CHAIN-REACTION - INVITED COMMENTARY", Journal of the American College of Surgeons, 187(2), 1998, pp. 188-190
71. HSUEH EC; GUPTA RK; GLASS EC; YEE R; QI K; MORTON DL
    POSITRON-EMISSION-TOMOGRAPHY PLUS SERUM TA90 IMMUNE-COMPLEX ASSAY FORDETECTION OF OCCULT METASTATIC MELANOMA
    Journal of the American College of Surgeons
    
    E.C. Hsueh et al., "POSITRON-EMISSION-TOMOGRAPHY PLUS SERUM TA90 IMMUNE-COMPLEX ASSAY FORDETECTION OF OCCULT METASTATIC MELANOMA", Journal of the American College of Surgeons, 187(2), 1998, pp. 191-197
72. HSUEH EC; FAMATIGA E; GUPTA RK; QI K; MORTON DL
    ENHANCEMENT OF COMPLEMENT-DEPENDENT CYTOTOXICITY BY POLYVALENT MELANOMA CELL VACCINE (CANCERVAX) - CORRELATION WITH SURVIVAL
    Annals of surgical oncology
    
    E.C. Hsueh et al., "ENHANCEMENT OF COMPLEMENT-DEPENDENT CYTOTOXICITY BY POLYVALENT MELANOMA CELL VACCINE (CANCERVAX) - CORRELATION WITH SURVIVAL", Annals of surgical oncology, 5(7), 1998, pp. 595-602
73. DABROWSKA DM; ELASHOFF RM; HO W; MORTON DL
    IDENTIFYING PREDICTIVE FACTORS IN MELANOMA PROGRESSION
    Oncology Reports
    
    D.M. Dabrowska et al., "IDENTIFYING PREDICTIVE FACTORS IN MELANOMA PROGRESSION", Oncology Reports, 5(3), 1998, pp. 569-575
74. COCHRAN AJ; ELASHOFF D; MORTON DL; ELASHOFF R
    INDIVIDUALIZED PROGNOSIS FOR MELANOMA PATIENTS
    Modern pathology
    
    A.J. Cochran et al., "INDIVIDUALIZED PROGNOSIS FOR MELANOMA PATIENTS", Modern pathology, 11(1), 1998, pp. 48-48
75. HSUEH EC; GUPTA RK; QI K; MORTON DL
    CORRELATION OF SPECIFIC IMMUNE-RESPONSES WITH SURVIVAL IN MELANOMA PATIENTS WITH DISTANT METASTASES RECEIVING POLYVALENT MELANOMA CELL VACCINE
    Journal of clinical oncology
    
    E.C. Hsueh et al., "CORRELATION OF SPECIFIC IMMUNE-RESPONSES WITH SURVIVAL IN MELANOMA PATIENTS WITH DISTANT METASTASES RECEIVING POLYVALENT MELANOMA CELL VACCINE", Journal of clinical oncology, 16(9), 1998, pp. 2913-2920
76. HOON DSB; OKAMOTO T; WANG HJ; ELASHOFF R; NIZZE AJ; FOSHAG LJ; GAMMON G; MORTON DL
    IS THE SURVIVAL OF MELANOMA PATIENTS RECEIVING POLYVALENT MELANOMA CELL VACCINE LINKED TO THE HUMAN-LEUKOCYTE ANTIGEN PHENOTYPE OF PATIENTS
    Journal of clinical oncology
    
    D.S.B. Hoon et al., "IS THE SURVIVAL OF MELANOMA PATIENTS RECEIVING POLYVALENT MELANOMA CELL VACCINE LINKED TO THE HUMAN-LEUKOCYTE ANTIGEN PHENOTYPE OF PATIENTS", Journal of clinical oncology, 16(4), 1998, pp. 1430-1437
77. TAKAHASHI T; CONFORTI A; KIKUMOTO Y; HOON DSB; MORTON DL; IRIE RF
    AUGMENTATION OF IGM ANTIBODY TO GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDEBY MELANOMA CELL VACCINE
    Journal of clinical immunology
    
    T. Takahashi et al., "AUGMENTATION OF IGM ANTIBODY TO GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDEBY MELANOMA CELL VACCINE", Journal of clinical immunology, 18(4), 1998, pp. 299-305
78. LUCCI A; CHO WI; HAN TY; GIULIANO AE; MORTON DL; CABOT MC
    GLUCOSYLCERAMIDE - A MARKER FOR MULTIPLE-DRUG RESISTANT CANCERS
    Anticancer research
    
    A. Lucci et al., "GLUCOSYLCERAMIDE - A MARKER FOR MULTIPLE-DRUG RESISTANT CANCERS", Anticancer research, 18(1B), 1998, pp. 475-480
79. GLASS EC; ESSNER R; MORTON DL
    KINETICS OF 3 LYMPHOSCINTIGRAPHIC AGENTS IN PATIENTS WITH CUTANEOUS MELANOMA
    The Journal of nuclear medicine
    
    E.C. Glass et al., "KINETICS OF 3 LYMPHOSCINTIGRAPHIC AGENTS IN PATIENTS WITH CUTANEOUS MELANOMA", The Journal of nuclear medicine, 39(7), 1998, pp. 1185-1190
80. Chan, AD; Morton, DL
    Active immunotherapy with allogeneic tumor cell vaccines: Present status
    SEMINARS IN ONCOLOGY
    
    A.D. Chan e D.L. Morton, "Active immunotherapy with allogeneic tumor cell vaccines: Present status", SEMIN ONCOL, 25(6), 1998, pp. 611-622
81. Ollila, DW; Stern, SL; Morton, DL
    Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma
    JOURNAL OF SURGICAL ONCOLOGY
    
    D.W. Ollila et al., "Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma", J SURG ONC, 69(4), 1998, pp. 206-211
82. HUANG SKS; OKAMOTO T; MORTON DL; HOON DSB
    ANTIBODY-RESPONSES TO MELANOMA MELANOCYTE AUTOANTIGENS IN MELANOMA PATIENTS/
    Journal of investigative dermatology
    
    S.K.S. Huang et al., "ANTIBODY-RESPONSES TO MELANOMA MELANOCYTE AUTOANTIGENS IN MELANOMA PATIENTS/", Journal of investigative dermatology, 111(4), 1998, pp. 662-667
83. Okamoto, T; Irie, RF; Fujii, S; Huang, SKS; Nizze, AJ; Morton, DL; Hoon, DSB
    Anti-tyrosinase-related protein-2 immune response in vitiligo patients andmelanoma patients receiving active-specific immunotherapy
    JOURNAL OF INVESTIGATIVE DERMATOLOGY
    
    T. Okamoto et al., "Anti-tyrosinase-related protein-2 immune response in vitiligo patients andmelanoma patients receiving active-specific immunotherapy", J INVES DER, 111(6), 1998, pp. 1034-1039
84. RAVINDRANATH MH; KELLEY MC; JONES RC; AMIRI AA; BAUER PM; MORTON DL
    RATIO OF IGG - IGM ANTIBODIES TO SIALYL LEWIS(X) AND GM(3) CORRELATESWITH TUMOR-GROWTH AFTER IMMUNIZATION WITH MELANOMA-CELL VACCINE WITH DIFFERENT ADJUVANTS IN MICE
    International journal of cancer
    
    M.H. Ravindranath et al., "RATIO OF IGG - IGM ANTIBODIES TO SIALYL LEWIS(X) AND GM(3) CORRELATESWITH TUMOR-GROWTH AFTER IMMUNIZATION WITH MELANOMA-CELL VACCINE WITH DIFFERENT ADJUVANTS IN MICE", International journal of cancer, 75(1), 1998, pp. 117-124
85. KELLEY MC; JONES RC; GUPTA RK; YEE R; STERN S; WANEK L; MORTON DL
    TUMOR-ASSOCIATED ANTIGEN TA-90 IMMUNE-COMPLEX ASSAY PREDICTS SUBCLINICAL METASTASIS AND SURVIVAL FOR PATIENTS WITH EARLY-STAGE MELANOMA
    Cancer
    
    M.C. Kelley et al., "TUMOR-ASSOCIATED ANTIGEN TA-90 IMMUNE-COMPLEX ASSAY PREDICTS SUBCLINICAL METASTASIS AND SURVIVAL FOR PATIENTS WITH EARLY-STAGE MELANOMA", Cancer, 83(7), 1998, pp. 1355-1361
86. MOORE FD; ROSENBERG SA; FOLKMAN JM; MORTON DL; BALCH CM; SPENCER FC
    DURABILITY OF COMPLETE RESPONSES IN PATIENTS WITH METASTATIC CANCER TREATED WITH HIGH-DOSE INTERLEUKIN-2 - IDENTIFICATION OF THE ANTIGENS MEDIATING RESPONSE - DISCUSSION
    Annals of surgery
    
    F.D. Moore et al., "DURABILITY OF COMPLETE RESPONSES IN PATIENTS WITH METASTATIC CANCER TREATED WITH HIGH-DOSE INTERLEUKIN-2 - IDENTIFICATION OF THE ANTIGENS MEDIATING RESPONSE - DISCUSSION", Annals of surgery, 228(3), 1998, pp. 317-319
87. MORTON DL
    INTRAOPERATIVE LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY - COMMUNITY STANDARD CARE OR CLINICAL INVESTIGATION
    The cancer journal from Scientific American
    
    D.L. Morton, "INTRAOPERATIVE LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY - COMMUNITY STANDARD CARE OR CLINICAL INVESTIGATION", The cancer journal from Scientific American, 3(6), 1997, pp. 328-330
88. HSUEH EC; GUPTA RK; QI K; YEE R; LEOPOLDO ZC; MORTON DL
    TA90 IMMUNE-COMPLEX PREDICTS SURVIVAL FOLLOWING SURGERY AND ADJUVANT VACCINE IMMUNOTHERAPY FOR STAGE-IV MELANOMA
    The cancer journal from Scientific American
    
    E.C. Hsueh et al., "TA90 IMMUNE-COMPLEX PREDICTS SURVIVAL FOLLOWING SURGERY AND ADJUVANT VACCINE IMMUNOTHERAPY FOR STAGE-IV MELANOMA", The cancer journal from Scientific American, 3(6), 1997, pp. 364-370
89. DALE PS; FOSHAG LJ; WANEK LA; MORTON DL
    METASTASIS OF PRIMARY MELANOMA TO 2 SEPARATE LYMPH-NODE BASINS - PROGNOSTIC-SIGNIFICANCE
    Annals of surgical oncology
    
    P.S. Dale et al., "METASTASIS OF PRIMARY MELANOMA TO 2 SEPARATE LYMPH-NODE BASINS - PROGNOSTIC-SIGNIFICANCE", Annals of surgical oncology, 4(1), 1997, pp. 13-18
90. FARZAD Z; MCBRIDE WH; OGBECHI H; ASNONGHOLTHOFF C; MORTON DL; COCHRAN AJ
    LYMPHOCYTES FROM LYMPH-NODES AT DIFFERENT DISTANCES FROM HUMAN-MELANOMA VARY IN THEIR CAPACITY TO INHIBIT ENHANCE TUMOR-CELL GROWTH IN-VITRO/
    Melanoma research
    
    Z. Farzad et al., "LYMPHOCYTES FROM LYMPH-NODES AT DIFFERENT DISTANCES FROM HUMAN-MELANOMA VARY IN THEIR CAPACITY TO INHIBIT ENHANCE TUMOR-CELL GROWTH IN-VITRO/", Melanoma research, 7, 1997, pp. 59-65
91. RAVINDRANATH MH; BAUER PM; AMIRI AA; MIRI SM; KELLEY MC; JONES RC; MORTON DL
    CELLULAR CANCER VACCINE INDUCES DELAYED-TYPE HYPERSENSITIVITY REACTION AND AUGMENTS ANTIBODY-RESPONSE TO TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS (SIALYL LE(A), SIALYL LE(X), GD(3) AND GM(2)) BETTER THAN SOLUBLELYSATE CANCER VACCINE
    Anti-cancer drugs
    
    M.H. Ravindranath et al., "CELLULAR CANCER VACCINE INDUCES DELAYED-TYPE HYPERSENSITIVITY REACTION AND AUGMENTS ANTIBODY-RESPONSE TO TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS (SIALYL LE(A), SIALYL LE(X), GD(3) AND GM(2)) BETTER THAN SOLUBLELYSATE CANCER VACCINE", Anti-cancer drugs, 8(3), 1997, pp. 217-224
92. RAVINDRANATH MH; MORTON DL
    IMMUNOGENICITY OF MEMBRANE-BOUND GANGLIOSIDES IN VIABLE WHOLE-CELL VACCINES
    Cancer investigation
    
    M.H. Ravindranath e D.L. Morton, "IMMUNOGENICITY OF MEMBRANE-BOUND GANGLIOSIDES IN VIABLE WHOLE-CELL VACCINES", Cancer investigation, 15(5), 1997, pp. 491-499
93. WEN DR; MORTON DL; COCHRAN AJ
    THE PATHOLOGY OF MELANOMA PATIENTS WITH NEGATIVE SENTINEL NODES WHO SUBSEQUENTLY DEVELOP IPSILATERAL NODAL METASTASES
    Laboratory investigation
    
    D.R. Wen et al., "THE PATHOLOGY OF MELANOMA PATIENTS WITH NEGATIVE SENTINEL NODES WHO SUBSEQUENTLY DEVELOP IPSILATERAL NODAL METASTASES", Laboratory investigation, 76(1), 1997, pp. 263-263
94. MORTON DL
    INTRODUCTION - SENTINEL LYMPHADENECTOMY FOR PATIENTS WITH CLINICAL STAGE-I MELANOMA
    Journal of surgical oncology
    
    D.L. Morton, "INTRODUCTION - SENTINEL LYMPHADENECTOMY FOR PATIENTS WITH CLINICAL STAGE-I MELANOMA", Journal of surgical oncology, 66(4), 1997, pp. 267-269
95. CONFORTI AM; OLLILA DW; KELLEY MC; GAMMON G; MORTON DL
    UPDATE ON ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA VACCINES
    Journal of surgical oncology
    
    A.M. Conforti et al., "UPDATE ON ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA VACCINES", Journal of surgical oncology, 66(1), 1997, pp. 55-64
96. TAKAHASHI T; IRIE RF; MORTON DL; HOON DSB
    RECOGNITION OF GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDE BY BOTH HLA-A2 RESTRICTED CTL LINES AND ANTIBODIES FROM MELANOMA PATIENTS
    Cellular immunology
    
    T. Takahashi et al., "RECOGNITION OF GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDE BY BOTH HLA-A2 RESTRICTED CTL LINES AND ANTIBODIES FROM MELANOMA PATIENTS", Cellular immunology, 178(2), 1997, pp. 162-171
97. SARANTOU T; CHI DDJ; GARRISON DA; CONRAD AJ; SCHMID P; MORTON DL; HOON DSB
    MELANOMA-ASSOCIATED ANTIGENS AS MESSENGER-RNA DETECTION MARKERS FOR MELANOMA
    Cancer research
    
    T. Sarantou et al., "MELANOMA-ASSOCIATED ANTIGENS AS MESSENGER-RNA DETECTION MARKERS FOR MELANOMA", Cancer research, 57(7), 1997, pp. 1371-1376
98. RAVINDRANATH MH; AMIRI AA; BAUER PM; KELLEY MC; ESSNER R; MORTON DL
    ENDOTHELIAL-SELECTIN LIGANDS SIALYL LEWIS(X) AND SIALYL LEWIS(A) ARE DIFFERENTIATION ANTIGENS IMMUNOGENIC IN HUMAN-MELANOMA
    Cancer
    
    M.H. Ravindranath et al., "ENDOTHELIAL-SELECTIN LIGANDS SIALYL LEWIS(X) AND SIALYL LEWIS(A) ARE DIFFERENTIATION ANTIGENS IMMUNOGENIC IN HUMAN-MELANOMA", Cancer, 79(9), 1997, pp. 1686-1697
99. CHI DDJ; MERCHANT RE; RAND R; CONRAD AJ; GARRISON D; TURNER R; MORTON DL; HOON DSB
    MOLECULAR-DETECTION OF TUMOR-ASSOCIATED ANTIGENS SHARED BY HUMAN CUTANEOUS MELANOMAS AND GLIOMAS
    The American journal of pathology
    
    D.D.J. Chi et al., "MOLECULAR-DETECTION OF TUMOR-ASSOCIATED ANTIGENS SHARED BY HUMAN CUTANEOUS MELANOMAS AND GLIOMAS", The American journal of pathology, 150(6), 1997, pp. 2143-2152
100. JONES RC; KELLEY M; GUPTA RK; NIZZE JA; YEE R; LEOPOLDO Z; QI K; STERN S; MORTON DL
     IMMUNE-RESPONSE TO POLYVALENT MELANOMA CELL VACCINE IN AJCC STAGE-IIIMELANOMA - AN IMMUNOLOGICAL SURVIVAL MODEL
     Annals of surgical oncology
     
     R.C. Jones et al., "IMMUNE-RESPONSE TO POLYVALENT MELANOMA CELL VACCINE IN AJCC STAGE-IIIMELANOMA - AN IMMUNOLOGICAL SURVIVAL MODEL", Annals of surgical oncology, 3(5), 1996, pp. 437-445